When was Tethis founded?

Tethis was founded in 2004 and raised its 1st funding round 6 years after it was founded.

Where is Tethis located?

Tethis is headquartered in Milan, Italy. It is registered at 1131 CAMPUS DRIVE WEST, MORGANVILLE, United States, 07751, NJ.

How many employees does Tethis have?

As of Jul 31, 2026, the latest employee count at Tethis is 36.

Is Tethis a funded company?

Tethis is a funded company, having raised a total of $15.3M across 5 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on May 26, 2010.

When was the latest funding round of Tethis?

Tethis' latest funding was a $***** PE round on Jan 14, 2025, with participation from 1 investor.

Where does Tethis rank among its competitors?

Tethis ranks 10th amongst 172 active competitors, of which 57 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was GRAIL, which secured $110M in Jun, 2026.

Who are the top competitors of Tethis?

Tethis' top competitors include Exact Sciences, GRAIL and UDX. Among them, GRAIL secured the most recent funding round in June, 2026.

Tethis - 2026 Company Profile, Team, Funding & Competitors

Company Details

Provider of automated solutions for in liquid biopsy. It offer a pre‑analytical workstation for blood samples at the collection siteand separates plasma and stabilizes cellular fraction directly on nanocoated SmartBioSurface microscope slides ideal for detecting circulating tumor cells (CTCs) and preserving cell-free plasma.

Website: tethis-lab.com
Registered Address: 1131 CAMPUS DRIVE WEST, MORGANVILLE, United States, 07751, NJ

Key Metrics

Founded Year

2004

Location

Milan, Italy

Stage

Series A

Total Funding

$15.3M in 5 rounds

Latest Funding Round

PE, Jan 14, 2025, $*****

Investors

Indaco Venture Partners & 6 more

Ranked

10^th among 172 active competitors

Employee Count

36 as on Jul 31, 2026

Similar Companies

Exact Sciences & 247 more

View Tethis' full profile

Tethis is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
TETHIS LABS INC. CIN: 001t000000WoSgFAAV , United States, Active	Oct 07, 2019	-	-	-

Tethis has raised a total funding of $15.3M over 5 rounds. Its first funding round was on May 26, 2010. Its latest funding round was a PE round on Jan 14, 2025 for $*****. 1 investor participated in its latest round. Tethis has 7 institutional investors.

Here is the list of recent funding rounds of Tethis:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 14, 2025	2223445	PE	5120297	1379598	4625821	4250757
Aug 31, 2018	8103449	Grant (prize money)	8915596	5811501	4090443	EIC Fund
May 01, 2018	3745848	Grant (prize money)	5111236	8496259	4876323	Europa

Access funding benchmarks and valuations. Sign up today!

View details of Tethis's funding rounds and investors

Tethis' employee count trend

Tethis has 36 employees as of Jul 26. Here is Tethis's employee count trend over the years:

Uncover Tethis' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Tethis include Exact Sciences, GRAIL and UDX. Here is the list of Top 10 competitors of Tethis, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Exact Sciences 1995, Madison (United States), Acquired	Provider of non-invasive molecular diagnostic testing solutions for cancer	-	Petrillo Capital, Back Bay Group & 8 others	71/100
2nd	GRAIL 2016, Menlo Park (United States), Public	Developer of a screening platform for circulating tumor DNA to detect cancer	$2B	Arch Venture Partners, Hillhouse & 52 others	69/100
3rd	UDX 2012, Seville (Spain), Series C	Developer of non-invasive blood-based diagnostics for cancer	$105M	Quest Diagnostics, Olympus & 6 others	67/100
4th	Delfi Diagnostics 2019, Baltimore (United States), Series B	Provider of DNA sequencing for cancer detection	$332M	DFJ Growth, Orbimed & 19 others	64/100
5th	Volition 1995, Gembloux (Belgium), Public	Developer of cancer diagnostic tests	-	Namur Invest, Belgium & 1 others	61/100
6th	Biocartis 2007, Mechelen (Belgium), Public	Manufacturer of automated molecular diagnostic systems for oncology biomarker testing	$305M	Johnson & Johnson Innovation – JJDC, Advent Life Sciences ... & 18 others	58/100
7th	Angle 1994, Surrey (Canada), Public	Developer of cancer cell capture and analysis equipment	-	WG Partners, Mercia & 1 others	57/100
8th	Datar Genetics 1992, Nashik (India), Early Stage	Provider of liquid biopsy-based cancer diagnostic test	$2.98M	Alkemi Growth Capital, Brand Capital & 14 others	56/100
9th	Biovica 2009, Uppsala (Sweden), Public	Drug response monitoring assay	$4.27M	EIC Fund, Europa	56/100
10th	Tethis 2004, Milan (Italy), Series A	Provider of automated solutions for in liquid biopsy	$15.3M	Indaco Venture Partners, EIC Fund & 5 others	55/100